PYCR3 modulates mtDNA copy number to drive proliferation and doxorubicin resistance in triple-negative breast cancer
The International Journal of Biochemistry & Cell Biology · 2024-06 · 171 · 106581
DOI: 10.1016/j.biocel.2024.106581 ↗Kurz gefasst
Fachartikel in der Zeitschrift The International Journal of Biochemistry & Cell Biology, 2024-06. Verfasst von Feifei Zhuang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Yantaishan Hospital, Yantai, Shandong, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Doxorubicin, Cell Proliferation, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) poses significant challenges in treatment due to its aggressive nature and limited therapeutic targets. Understanding the underlying molecular mechanisms driving TNBC progression and chemotherapy resistance is imperative for developing effective therapeutic strategies. Thus, in this study, we aimed to elucidate the role of pyrroline-5-carboxylate reductase 3 (PYCR3) in TNBC pathogenesis and therapeutic response. We observed that PYCR3 is significantly upregulated in TNBC specimens compared to normal breast tissues, correlating with a poorer prognosis in TNBC patients. Knockdown of PYCR3 not only suppresses TNBC cell proliferation but also reverses acquired resistance of TNBC cells to doxorubicin, a commonly used chemotherapeutic agent. Mechanistically, we identified the mitochondrial localization of PYCR3 in TNBC cells and demonstrated its impact on TNBC cell proliferation and sensitivity to doxorubicin through the regulation of mtDNA copy number and mitochondrial respiration. Importantly, Selective reduction of mtDNA copy number using the mtDNA replication inhibitor 2', 3'-dideoxycytidine effectively recapitulates the phenotypic effects observed in PYCR3 knockout, resulting in decreased TNBC cell proliferation and the reversal of doxorubicin resistance through apoptosis induction. Thus, our study underscores the clinical relevance of PYCR3 and highlight its potential as a therapeutic target in TNBC management. By elucidating the functional significance of PYCR3 in TNBC, our findings contribute to a deeper understanding of TNBC biology and provide a foundation for developing novel therapeutic strategies aimed at improving patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Yantaishan Hospital, Yantai, Shandong, China.
- Department of Medical Oncology, Yantaishan Hospital, Yantai, Shandong, China. Electronic address: ytsyyll2023@163.com.
Zitieren
APA
Zhuang, F., Huang, S., & Liu, L. (2024). PYCR3 modulates mtDNA copy number to drive proliferation and doxorubicin resistance in triple-negative breast cancer. The International Journal of Biochemistry & Cell Biology, 171, 106581. https://doi.org/10.1016/j.biocel.2024.106581
Vancouver
Zhuang F, Huang S, Liu L. PYCR3 modulates mtDNA copy number to drive proliferation and doxorubicin resistance in triple-negative breast cancer. The International Journal of Biochemistry & Cell Biology. 2024;171:106581. doi:10.1016/j.biocel.2024.106581
BibTeX
@article{Zhuang2024,
author = {Zhuang, Feifei and Huang, Shaoyan and Liu, Lei},
title = {PYCR3 modulates mtDNA copy number to drive proliferation and doxorubicin resistance in triple-negative breast cancer},
journal = {The International Journal of Biochemistry & Cell Biology},
year = {2024},
volume = {171},
pages = {106581},
doi = {10.1016/j.biocel.2024.106581}
}
EUVIMED